... considered to have N1 diseaseclose tothe primary lung tumor. In 19 cases (59%) the tumor was in the right lung. In 22 cases (69%) the tumorwas located in the upper lobes.Radiotherapy was delivered ... normal lungandto facilitate monitoring the respi-ratory motion. The median area of the fields was 72 cm2 (typically 8 cmì 9 cm) andthe median PTV volume was 150 cm3 (range:28–1110). The ... as lung cancer. It is more convenient for the patients and reduces health care costs.This study reports our results on patients with medically inoperable, early stage, non -small cell lung cancer...
... [10,11].MethodsSources of cell lines and culture The PC-9 lung tumor cell line was kindly provided byRoche (Basel, Switzerland); the A 549 and H460 cell lineswere purchased from the American Type Culture ... the H1975 cell line and five of the H1650 cell line with 4- μ m sections for IHC analysisfrom theCell Signaling Technology laboratory.Study population and tumor pathologyTwenty-six stage IV ... compared with IHC results in five non -small- cell lungcancer (NSCLC) cell lines and tumor samples from 78 stage IV NSCLC patients.Results: IHC correctly identified del 19 in the H1650 and PC9 cell...
... radiotherapy (TRT) com-bined with chemotherapy represents the standard ofcar e in the management of limited -stage small- cell lung cancer (LS-SCLC), the optimal radiation schedule and total ... radiotherapy is feasible concurrent with chemotherapy for limited -stage small- celllung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys20 04, 59 :46 0 -46 8.7. ... interruptions to palliate the toxicity from concurrent chemoradiation for limited smallcell lung cancer decreases survival and disease control. LungCancer 2001,33: 249 -258.26. Cisplatin, etoposide, and...
... Rad iotherapy, Oligometastases, Non -Small CellLung Cancer BackgroundNon -small celllungcancer (NSCLC) is the leadingcause of cancer mortality in the United States [1].Patients withstage ... Standard therapy for metastatic non smallcelllungcancer (NSCLC) includes palliative systemicchemotherapy and/ or radiotherapy. Recent studies of patients with limited metastases treated with ... categorizedas stage III NSCLC, 38 patients (26.0%) with initial lim-ited stage IV NSCLC and 14 patients (9.6%) with stage I/II NSCLC who progressed to limited metastatic stage IV. Fifty-five of the 94 patients...
... primary tumors of theliverand of the lungs and metastases in theliverand lungs [1,2]. At the same time,laser-induced thermotherapy (LITT) or high frequency-induced thermotherapy (HITT) became ... (range: 1.6 to 16 .4 %) and 5.3% (range: 1.2 to 14. 3%), respectively.Yet, these volumes andthe planning target volumes werestill small in comparison tothe total volume of the lungs and, up to this ... with peripheral stage Inon -small celllung cancer. LungCancer 1999, 26:137- 142 .23. Slotman BJ, Antonisse IE, Njo KH: Limited field irradiation inearly stage (T1-2N0) non -small celllung cancer. ...
... tumorshrinkage, with no additional toxicity, and gave the patient the possibility to undergo a lobectomy ratherthan a pneumectomy, withthe obvious advantages of aless invasive and more limited surgical ... appeared to measure 65 ì 41 mm. The safety profile was good, with patient reportinggrade 1 ane mia, grade 3 neutropenia without fever,weight loss inferior to 10% and asthenia. Therefore, the treatment ... chemotherapy with single agentdocetaxel in a patient with advanced non small celllung cancer Ferdinando Riccardi1*, Giuseppe Di Lorenzo1, Carlo Buonerba1, Guglielmo Monaco2, Roberto Monaco3,Mimma...
... factors associated with SARP. The incidences of SARP in the group with NTCP > 4. 2% and NTCP 4. 2% were 43 .5% and 1 .4% , respectively (p < 0.01). The incidences of SARP in the group with ... for 94 patients; the incidences ofSARP in the group with NTCP > 4. 2% and NTCP ≤ 4. 2%were 43 .5% and 1 .4% , respectively (p < 0.01); the inci-dences of SARP in the group with V10 ≤50% and ... statisti-cally; the incidences of SARP in the group with NTCP > 4. 2% and NTCP ≤ 4. 2% were 43 .5% and 1 .4% , respectively(p < 0.01). The incidences of SARP in the group with V10≤ 50% and V10 >50%...
... allpatients, and it was 81% for thestage IA patients treated with 48 Gy and 74% for thestage IB patients, with nosignificant diffe rence between them ( p =0.35).Two stage IA patients treated with 44 ... 70all patients stage IA patients treated with 48 Gy in 4 fractions stage IB patients treated with 52 Gy in 4 fractionsall patients stage IA patients treated with 48 Gy in 4 fractions stage IB patients ... 1 24 NSCLC patients treated with SBRT, 87 had stage IA and 37 had stage IB disease. Tw o stage IApatients with tumors of less than 1.5 cm in diameterwere treated with 44 Gy in 4 fractions, and...
... .002 .961 4. 638 .031 .895 . 344 3~5 cm .002 .961 10.977 .001 4. 541 .0335~7 cm 4. 638 .031 10.977 .001 .108 . 742 >7 cm .895 . 344 4. 541 .033 .108 . 742 Wu et al. Radiation Oncology 2011, 6: 84 http://www.ro-journal.com/content/6/1/ 84 Page ... mortality of the patients with stage II was 4. 0 64 times higher than that of the patients with stageI (p = 0.015). Systemic chemotherapy increased the risk of death of the patients with early stage NSCLCin ... (range, 142 .8~ 240 .0 Gy) in 24 patients with tumor size of 3~5 cm, 165.5 Gy (range, 142 .8~212.2 G y)in 10 patients with tumor size of 5~7 cm and 144 .0 Gy(range, 142 .8~1 84. 8 Gy) in 9 patients with...
... 18 to 22 25 > 25 to 28Oesophagus 1 24 > 24 to 27 27 > 27 to 28.5Ipsilateral Brachial Plexus 1 24 > 24 to 26 27 > 27 to 29Heart 1 24 > 24 to 26 27 > 27 to 29Trachea and ... mini-mum of 40 hours, in line withthe RTOG protocol 0618.Ratio of 50% Prescription Isodose Volume tothe PTV (R50%) from a total of 22 patients withstage IA tumours and4 patients withstage 1B ... stereotacticradiotherapy. Therefore, an additional planning study wasperformed in 22 stage IA and4stage 1B non -small cell lungcancer patients in order to develop and evaluate the planning guidelines...
... retrospectively reviewed the records of 115 patients with non -small cell lung cancer treated at our institution with definitive radiation therapy with or without concurrentchemotherapy (CHT). All ... regional recurrence, and distant metastases (DM).Results: The median follow-up time was 18 months (3 to 44 months) among all patients and 27months (6 to 44 months) among survivors. The median overall ... coded the patient data-base, conducted the analysis and wrote the manuscriptdraft. JYC designed the project, analyzed the data and revised the manuscript. AK helped withthe database and data...
... chemotherapy for stage III non -small- celllung cancer. JClin Oncol 1995, 13 :45 2 -45 8. 34. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S: Hyperfraction-ated radiation therapy with or without ... Surg20 04, 128 :41 4 -41 9.39. The International Adjuvant LungCancer Collaborative Trial Group:Cisplatin-based adjuvant chemotherapy in patients with completely resected non -small celllung cancer. ... modality trials of theCancerand Leukemia Group Bin stage III non -small- celllung cancer: analysis of factorsinfluencing survival and toxicity. Ann Oncol 20 04, 15:1033-1 041 .22. Zatloukal P,...
... patients with non -small celllung cancer. J Thorac Oncol 2010, 5:825-9. 4. Ou SH, Zell JA: Validation study of the proposed IASLC staging revisions of the T4 and M non -small celllungcancer descriptors ... radiotherapy is the currentstandard of care for pati ents with locally advan ced (stage IIIA andstage IIIB) NSCLC. However, regardless of the total dose of radiation andthe optimal chemotherapy, the ... Lung Cancer Registry. Prognosis of 6 644 resected non -small celllung cancersin Japan: a Japanese lungcancer registry study. LungCancer 2005,50:227- 34. 11. Andre F, Grunenwald D, Pignon JP, Dujon...
... growthfactor receptor expression or activation in operable non -small cell lung cancer. LungCancer 2005, 48 (1) :47 -57. 40 . Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M,Ramirez ... 2-mediatedpathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005, 4( 9): 144 8-55, (Georgia).7. Sahin M, Sahin E, Gümüslü S: Cyclooxygenase-2 in cancer and angiogenesis. ... anepidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non -small celllungcancer (NSCLC)....